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Willingness to test for BRCA1/2 in high risk women: Influenced by
risk perception and family experience, rather than by objective or
subjective numeracy?
Talya Miron-Shatz∗ Yaniv Hanoch † Benjamin A. Katz‡ Glen M. Doniger§
Elissa M. Ozanne¶
Abstract
Genetic testing for breast and ovarian cancer can help target prevention programs, and possibly reduce morbidity and
mortality. A positive result of BRCA1/2 is a substantial risk factor for breast and ovarian cancer, and its detection often leads to
risk reduction interventions such as increased screening, prophylactic mastectomy and oophorectomy. We examined predictors
of the decision to undergo cancer related genetic testing: perceived risk, family risk of breast or ovarian cancer, and numeracy
as predictors of the decision to test among women at high risk of breast cancer. Stepwise regression analysis of survey
responses from 459 women registered in the Cancer Genetics Network revealed greater likelihood to test for women with
more family history, higher perceived risk of mutation, or Ashkenazi descent. Neither subjective nor objective numeracy was
associated with the decision to test, although we replicated an earlier finding that subjective numeracy predicted willingness
to pay for testing. Findings underscore the need for genetic counselling that disentangles risk perception from objective
information to promote better decision-making in the context of genetic testing. Highlighting these factors is crucial for public
health campaigns, as well as to clinic-based testing and direct-to-consumer testing.
Keywords: willingness to test, genetic testing, breast cancer, BRCA1 and 2, subjective numeracy, family history. early
detection.
1 Introduction
Breast cancer is the most prevalent cancer among women
(Siegel, Naishadham & Jemal, 2012). For decades, public
health resources and campaigns have been dedicated to early
detection and education (Lee et al., 2014) to women in high-
risk groups. The BRCA1 and BRCA2 gene mutations, for ex-
ample, are a known genetic risk factor for the development
of breast and ovarian cancer (Squiers et al., 2010). Their
detection allows women to be better informed and proactive
about future health decisions, and indeed, detection with ge-
netic testing has become more prevalent (Kolor et al, 2012;
This research was supported by American Cancer Society Grant No.
MRSG112037 (EMO), Cancer Genetics Network RFA CA–97-004, RFA
CA–97-019, RFP No. N01–PC–55049–40, a University of Plymouth
award (YH), European Research Council Marie Curie Reintegration Grant
No. PIRG7–GA–2010–268224 (TMS), and the Research Authority of the
Ono Academic College. The authors wish to thank Dr. David Zucker of the
Hebrew University for invaluable statistical guidance.
Copyright: © 2015. The authors license this article under the terms of
the Creative Commons Attribution 3.0 License.
∗Center for Medical Decision Making, Ono Academic College, 104 Za-
hal St., Kiryat Ono 55000, Israel. E-mail: talyam@ono.ac.il.
†School of Psychology, Plymouth University, UK
‡Department of Psychology, Hebrew University of Jerusalem, Israel.
§Center for Medical Decision Making, Ono Academic College, Israel
¶Dartmouth Institute for Health Policy and Clinical Practice, Geisel
School of Medicine at Dartmouth, USA.
Myriad, 2007). As Direct-to-Consumer (DTC) genetic tests
proliferate, the decision of whether to undergo genetic test-
ing is often in the individual’s own hands. This was the case
when we conducted our study. Indeed, the availability of
DTC testing for BRCA in the US has ebbed and flowed in
the past few years (Food and Drug Administration, 2013).
With the recent US Supreme Court decision in Association
for Molecular Pathology v. Myriad Genetics, Inc. (2013),
patent rights for the BRCA1/2 genes were revoked, opening
up the genetic testing market to competition.
With the growing accessibility to genetic tests, patients
might want to test, and still be apprehensive of testing:
among 69 patients who participated in semi-structured in-
terviews on testing, many expressed concerns regarding dis-
crimination, and psychological harm due to the testing re-
sults (Gray et al., 2013). Large-scale public health studies
show that testing rates in general tend to be suboptimal (e.g.,
Schlich-Bakker et al., 2007; Tao, Hooevr & Kent, 2012).
In order to encourage testing for the most at-risk, women
are currently advised to test for the BRCA1/2 gene muta-
tion if a family member has tested positive for it, or if a
close relative has been diagnosed with cancer (Moyer, 2014;
National Cancer Institute, 2013). Guidelines also estab-
lish a standard of care for women who have family mem-
bers with breast, ovarian, tubal, or peritoneal cancer that
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call for screening, genetic counselling, and, if appropriate,
BRCA testing (U.S. Preventive Services Task Force [USP-
STF], 2005; Moyer, 2014; National Comprehensive Cancer
Network [NCCN], 2013). In practice, a meta-analysis of 40
studies revealed that 59% of the women identified by the in-
vestigators as high-risk would test. However, testing rates
varied from 25% to 96%, depending on the study (Ropka,
Wenzel, Philips, Siadaty & Philbrick, 2006). Interestingly,
some work has shown that family history of breast can-
cer does not predict testing among women with or without
breast cancer (Bruno et al., 2010). In contrast, earlier inves-
tigations have shown that attitudes, cancer worry, knowl-
edge, religious involvement, and risk perception influence
women’s decision to undergo genetic testing (Chaliki et al.,
1995; Ruddy et al., 2010). Thus, the decision whether to
undergo genetic testing is complex (Sankar, Wolpe, Jones &
Cho, 2006).
Perceived risk of breast cancer, or genetic mutations as-
sociated with it may also predict decisions related to testing
for BRCA1/2. Prior work has found women who perceive
themselves to be at greater risk of developing the disease to
be more likely to test for BRCA1/2, and at a higher price
(Chaliki et al., 1995; Ruddy et al., 2010). Further, women
at increased risk for breast cancer show significantly higher
levels of cancer-specific distress (but not general distress)
relative to a comparison group (Rees, Fry, Cull & Sutton,
2004).
Likelihood to test increases as cancer becomes less of a
theoretical concern, and more of a concrete fear. Women
40 years old or younger diagnosed with breast cancer are
more likely to have undergone genetic testing if they have
a first- or second-degree relative with breast or ovarian can-
cer (Ruddy et al., 2010). Indeed, family history of cancer is
not only a medical risk factor but is also associated with
a personal sense of vulnerability (Walter, Emery, Braith-
waite & Marteau, 2004). Such vulnerability may extend to
women in high-risk groups, even in the absence of a direct
family member afflicted with cancer (e.g., Ashkenazi de-
scent; Bowen, Burke, Culver, Press & Crystal, 2006). This
tendency, however, is not absolute. Medical communica-
tion about breast cancer within the family is often prob-
lematic, and women may not even be fully aware of their
family’s level of risk (Claes, et al., 2002; Julian-Reynier et
al., 2000). Alternately, some studies have examined spe-
cific groups, such as New York Latinas, and Blacks with
low numeracy levels, that tend to be less likely to pursue
testing, despite perceived vulnerability for BRCA1/2 muta-
tions: more competing life concerns minimize motivation
to get tested (Langford, Resincow, Roberts & Zikmund-
Fisher, 2007; Sussner, Jandorf, Thompson & Valdimarsdot-
tir, 2012).
The decision to test may be influenced by personal factors
as well as environmental factors. Numeracy, the ability to
understand and manipulate numbers, has been shown to play
a role in calculating various statistical estimates, includ-
ing understanding medical risk information (e.g., Hanoch,
Miron-Shatz & Himmelstein, 2010; Låg, Bauger, Lindberg
& Friborg, 2014 ; Schwartz, Woloshin, Black & Welch,
1997). Assumedly, higher levels of numeracy should be
associated with testing rates, so that women at higher risk
for developing breast cancer would be more likely to test,
and women at a lower risk would be less likely. Accord-
ingly, Lipkus, Peters, Kimmick, Liotcheva and Marcom
(2007) found that more numerate women tended to estimate
more accurately their breast cancer risks, and were signifi-
cantly more open to recommended risk management strate-
gies. Similarly, in a sample of 6,754 adult respondents to
the National Cancer Institute’s 2007 Health Information Na-
tional Trends Survey (HINTS), numeracy was found to di-
rectly lead to awareness of DTC genetic tests (Lanford, et
al., 2007). As far as we are aware, the present study is the
first to directly examine whether high numeracy informs the
decision to test.
Numeracy can be measured through objective, be-
havioural tests and subjective, self-report questionnaires.
Objective numeracy scales examine comprehension of fre-
quency, probability and percentages (Schwartz et al., 1997;
Lipkus, Samsa & Rimer, 2001). In contrast, the subjective
numeracy scale (SNS, Fagerlin et al., 2007) measures per-
ceived ability to perform various mathematical operations
and preference for the use of numeric rather than textual
information (Lipkus et al., 2007). SNS can differentiate
among people with objectively low and high numeracy skills
across different demographic groups: it is quicker to admin-
ister and provides a more agreeable experience for partici-
pants than the objective scale questions (Galesic & Garcia-
Retamero, 2010). Recently it has been shown that subjec-
tive, but not objective, numeracy predicted women’s deci-
sions to pay for breast cancer testing (Miron-Shatz, Hanoch,
Omer, Doniger & Ozanne, 2014).
To our knowledge, ours is the first examination of will-
ingness to test and actual testing behaviour among women
at high risk of breast cancer, involving perceived risk, fam-
ily risk, and numeracy, both subjective and objective. To
accomplish this, we recruited women with a family his-
tory of breast or ovarian cancer, from the registrants of the
Cancer Genetic Network (CGN), some of whom had pre-
viously tested, and had already received results. Analyses
were cross-sectional, but data were collected at different
time points, for different participants. The data allowed us
to test the following hypotheses: (i) high-risk women with
more relatives with breast or ovarian cancer will be more
likely to test; (ii) presence of a family member with a posi-
tive BRCA1/2 test result will be associated with greater like-
lihood of testing; (iii) women with higher perceived risk of
mutation and developing the disease will be more likely to
test, as well as those more worried that the test might find
illness; (iv) women with higher numeracy—both subjective
Judgment and Decision Making, Vol. 10, No. 4, July 2015 Willingness to test for BRCA1/2 gene mutation 388
and objective—will be more likely to test, with a greater
role for subjective numeracy given its emphasis on percep-
tion of numbers (Fagerlin et al., 2007); and, finally, (v) older
women will be more likely to test.
2 Method
2.1 Participants
Participants were 449 female registrants in the Cancer Ge-
netics Network (CGN), a US national population-based can-
cer registry. Inclusion criteria were: (a) unaffected by breast
or ovarian cancer, and (b) family members at a higher risk
for breast cancer. In this case, higher risk was defined as
having at least one relative diagnosed with breast cancer at
age 45 or younger, two or more diagnosed with breast cancer
at age 50 or younger, or at least one diagnosed with ovarian
cancer or male breast cancer. Because this was a higher-
risk group, participants had a greater probability of being
a carrier of the BRCA1/2 gene. Consent was obtained and
the survey completed via emails from the local CGN branch
(Appendix Table A1). The CGN also maintains a core data
set on each registrant and stores de-identified information
on non-financial socio-demographic and medical character-
istics made available to researchers with ethical approval.
The CGN did not maintain data concerning differing levels
of risk for breast cancer within the high-risk group.
2.2 Procedure
Respondents completed an online survey. They were as-
sured that no knowledge of genetics was required to par-
ticipate and that their identifying information would remain
confidential. Respondents were told that the survey would
take about 30 minutes. They had an option of receiving a
$30 gift card and could skip any question that made them
uncomfortable. Measurement of variables was after disclo-
sure of the genetic testing results and occurred at differ-
ent points in time for different participants. The dependent
variable investigated was whether the woman had tested for
the BRCA1/2 mutation. Predictor variables were number of
relatives with breast or ovarian cancer, presence of family
member(s) testing positive, being of Ashkenazi (Eastern Eu-
ropean Jewish) descent, perceived risk of having a mutation,
perceived risk of developing breast cancer, worry that the
test might find illness, objective numeracy, subjective nu-
meracy, and age. Though we refer to the independent vari-
ables studied as “predictor variables”, the dataset was cross-
sectional. Predictor variables were computed as follows:
Number of Relatives with Breast or Ovarian Cancer:
Number of relatives with breast or ovarian cancer (range
in dataset: 1 to 13, with an open-ended question) from the
CGN database.
Of Ashkenazi (Eastern European Jewish) Descent: Re-
sponse options for this CGN database variable were “Yes”,
“No”, or “Unknown” – “No” and “Unknown” were com-
bined for analysis purposes. Values of this variable were
“No or Unknown” (coded 0) or “Yes” (coded 1).
Family Member(s) with Positive Test Result: The con-
catenated responses to questions from the CGN database,
asking “Has anyone in your family ever tested positive for
a BRCA1 mutation?” and likewise for BRCA2. Response
options were “No”, “Yes”, “Not Sure”, and “Rather Not
Answer” (not selected by any participants). We recorded
the responses as “Yes” (coded ‘3’) if the response to either
question was “Yes”, “No” (coded 1) if the response to both
questions was “No”, and “Unknown” (coded 2) for all other
cases.
Perceived Risk of Having the BRCA1/2 Mutation: For
participants who had not previously tested, responses to the
survey question: “What do you think the chances are that
you have the BRCA1 or BRCA2 gene mutation?” For par-
ticipants who had previously tested, responses to the survey
question: “Before you were tested for the BRCA1 or BRCA2
gene mutation, what do you think was the chance that you
had the mutation?” Participants responded by placing an
“X” on a number line running from 0 to 100%.
Perceived Risk of Developing Breast Cancer: Partici-
pants who had not previously tested, responded to the fol-
lowing survey question: “What do you think is the chance
of you developing breast cancer?” Participants who had pre-
viously tested, responded to the survey question: “Before
you were tested for the BRCA1 or BRCA2 gene mutation,
what did you think was your chance of developing breast
cancer?” Again, participants responded by placing an “X”
on a number line running from 0% to 100%.
Number of Relatives with Breast or Ovarian Cancer:
Number of relatives with breast or ovarian cancer from the
CGN database.
Worried that Test Might Lead to Discovery of Illness:
Responses to this survey question were on a 5-point Likert
scale with options of “Not Worried At All” (1), “Slightly
Worried” (2), “Of Medium Worry” (3), “Worried” (4), and
“Very Worried” (5). Participants who had previously tested
were instructed to try to think of how worried they were
before they got tested.
Objective Numeracy: Respondents completed three sur-
vey questions to test facility with numbers (e.g., how many
of 1,000 coin flips would come up heads) (Schwartz et al.,
1997). Each question was scored as correct (1) or incorrect
(0). Total number correct was analysed.
Subjective Numeracy: As part of the survey, participants
completed the SNS (Fagerlin et al., 2007). The overall SNS
score analysed was the average rating across all eight SNS
questions, with one of the questions reverse coded.
Age: Participant age (in years) from the CGN database.
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Table 1: Correlations for predictors included in the regression analyses.
2 3 4 5 6 7 8 9
1. Perceived risk of mutation .553 −.052 .046 .027 −.066 .282 .083 .185
2. Perceived risk of developing breast cancer 1 −.107 .002 −.007 −.004 .120 −.027 .050
3. Objective Numeracy 1 .364 −.172 −.040 .009 .028 .058
4. Subjective Numeracy 1 −.171 −.065 .040 −.066 .018
5. Worry that the test might find illness 1 −.034 −.086 −.063 −.072
6. Age 1 .036 −.020 −.025
7. Number of relatives with breast or ovarian cancer 1 .131 .155
8. Presence of family member(s) testing positive 1 .080
9. Of Ashkenazi descent 1
2.3 Statistical analyses
Correlations were calculated between the main variables of
interest (see Table 1). Data were also analysed using step-
wise regression, in which the most important predictors are
selected from among the set of predictor variables. We ran
both forward and backward regressions, with the entry and
removal level set at 0.10 respectively (see Appendix tables
A2 and A3 for order of inclusion in the final regression anal-
ysis). Consistency of results across forward and backward
procedures confirms the importance of significant predic-
tors, irrespective of the variable selection process. P < 0.05
was considered statistically significant.
We examined predictors of whether participants had pre-
viously been tested for the BRCA 1/2 mutations. The same
set of predictors was entered a priori into all models: per-
ceived risk of mutation, perceived risk of developing breast
cancer, worry about a positive test result, number of rela-
tives with breast or ovarian cancer, family member(s) with
a positive BRCA testing result, age, and Ashkenazi descent.
Binary logistic regression was used to model previous test-
ing.
3 Results
Of 961 eligible participants invited to complete the online
survey, 459 (mean age = 50.44 years, sd = 7.45; 72% college
graduates; 78% married/cohabiting) consented and com-
pleted the survey (48% response rate). For total objective
numeracy (possible scores: 0 to 3), the range was 0–3, with
a mean of 1.97 and a standard deviation of 0.94. For SNS
(possible scores: 1 to 6), the range was 2–6, with a mean of
4.74 and a standard deviation of 0.82.
3.1 Previous testing
Of the 449 participants who responded to the question on
whether they had previously tested, 70% (N = 315) reported
that they had not previously tested for the BRCA1 or BRCA2
genetic mutation, and 30% (N = 134) reported that they had
previously tested.
A forward stepwise binary logistic regression predicting
previous testing limited analysis to the 325 participants who
both responded to the question regarding previous testing
and had data for all of the predictor variables (not tested: N
= 216; tested: N = 109). Analysis revealed statistically sig-
nificant effects of number of relatives with breast or ovarian
cancer (Wald χ2 = 3.86, P = 0.049, more likely to test with
more affected relatives; e.g., 1–2 affected relatives: 19%
tested, >2 relatives: 48% tested), and family member(s) test-
ing positive (Wald χ2 = 23.34, P < 0.001, more likely to
test with greater certainty of family member(s) testing pos-
itive; yes: 89% tested, no: 39% tested). Additional signif-
icant predictors were perceived risk of having a mutation
(Wald χ2 = 34.25, P < 0.001, more likely to test with higher
perceived risk; e.g., perceived risk ≤50%: 21% tested, per-
ceived risk >50%: 55% tested), Ashkenazi descent (Wald
χ
2 = 14.03, P < 0.001, more likely to test if of Ashkenazi
descent; Ashkenazi: 77% tested, not Ashkenazi/unknown:
28% tested), and young age (Wald χ2 = 4.01, P = 0.045,
more likely to test if older; e.g., <40 years: 19% tested,
≥40 years: 35% tested). Other predictors (objective nu-
meracy, subjective numeracy, perceived risk of developing
breast cancer, and worry that the test be positive) were not
included in the final model as they were not significant. Re-
sults were identical for the corresponding backward step-
wise logistic regression analysis, indicating that the signif-
icant predictors obtained in the forward model are predic-
tive of previous testing irrespective of the variable selection
process. Further, results were identical even when cancer
center was added as an additional predictor, indicating that,
relative to the other predictors, the particular cancer center
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participants came from did not have an appreciable effect on
decision to test.
Since the CGN dataset does not include information on
income, we used educational level as a proxy for socioeco-
nomic status (Grzywacz, Almeida, Neupert & Ettner, 2004).
Previous testing status did not differ by educational level,
with 28% (35/124) of participants with less than a college
degree and 30% (99/325) of college graduates reporting pre-
vious testing (χ2 = 0.21, P = 0.64).
3.2 Results of willingness to pay (WTP) anal-
yses in all participants
The current data set allowed us to re-examine the results of
Miron-Shatz et al. (2014) with the full sample, including
those who were tested as well those who were not (the only
ones used in the earlier study). Of particular interest are the
correlations of WTP with subjective and objective numer-
acy.
WTP was significantly correlated with subjective numer-
acy (r = .185, P < .001) but not with objective numeracy (r
= −0.062, P = .199), and these two correlations were sig-
nificantly different from one another (Steiger’s Z = 4.45, P
< .001) despite the substantial correlation between objec-
tive numeracy and subjective numeracy (r =.364, P < .001).
Although WTP is correlated with being tested (.429, by bis-
erial correlation), we have already pointed out that being
tested did not correlate with either type of numeracy, so
the difference between subjective and objective numeracy
in this sample cannot be explained by inclusion of subjects
who were tested. (In fact, the correlation of WTP with sub-
jective numeracy is also significantly higher than the biserial
correlation of subjective numeracy with being tested [.031].)
Educational level (less than college graduate vs. college
graduate or graduate school) could not explain the differen-
tial correlation between type of numeracy and WTP, as ed-
ucational level was correlated with both subjective (r =.161,
P = .001) and objective (r =.253, P < .001) numeracy, and
not with WTP (r = .037, P = .444).
Similarly, worry that the test might find illness could not
explain the differential correlation between type of numer-
acy and WTP, as worry was (negatively) correlated with both
subjective (r = -.171, P < .001) and objective (r = -.172, P <
.001) numeracy, and not with WTP (r = -.018, P = .714).
WTP was also significantly correlated with perceived risk
of having a mutation (r = .280, P < .001) and, unlike in the
more limited sample, WTP was significantly correlated with
perceived risk of developing breast cancer (r = .162, P =
.001).
Neither age (r = −.048, P = .321) nor presence of family
member(s) testing positive (r = .085, P = .077) predicted
WTP. However, unlike in the published sample of women
who had not tested, WTP was correlated with number of
relatives with breast or ovarian cancer (r = .147, P = .005)
and Ashkenazi descent (r = .155, P = .001).
4 Discussion
This study examined factors affecting the decision to test for
the BRCA 1/2 gene mutations in women reporting a fam-
ily history of breast and ovarian cancer. The findings indi-
cate that women with more family members with breast or
ovarian cancer, or with a family member who tested posi-
tive for the BRCA1/2 mutation are more likely to have un-
dergone BRCA1/2 genetic testing. In addition, women who
perceived a higher risk of carrying the mutation, those of
Ashkenazi descent and older women were more likely to
undergo testing.
Numeracy—both subjective and objective—did not influ-
ence whether women tested for BRCA1/2. While these re-
sults seem not to dovetail with earlier work, it should be
noted that the majority of earlier studies focus on the link
between numeracy and comprehension of risk information.
Furthermore, our results are not isolated. For example,
Vassy and colleagues (Vassy, O’Brian, Waxler, Park, De-
lahanty, Florez, et al., 2012), examined participants’ moti-
vation to change behaviour following genetic testing for di-
abetes. In their study, participants were classified as either
low-risk or high-risk. The Vassy et al. (2012) study showed
that among high risk individuals, numeracy levels were not
associated with motivation to alter behaviour, while in the
low-risk group, individuals with low-numeracy skills ex-
pressed greater motivation to change behaviour. Although
there are indications that numeracy is related to greater
awareness of DTC genetic testing (Agurs-Collins, Ferrer,
Ottenbacher, Waters, O’Connell & Hamilton, 2015), this re-
lationship is typically found among the general population,
whereas few studies examine this association in high-risk
individuals, as in our study.
Our results thus suggest that awareness of the statistical
relevance of undergoing genetic testing, and actually test-
ing, are unrelated to the ability to use or interpret the re-
sults. Rather, it is possible that the decision to undergo
testing is based not on comprehension of multiple factors,
but rather on a single cue or a one-reason-based heuristic
(Gigerenzer & Gaissmaier, 2011): having a family history.
That is, among the women who decide to test, their deci-
sion is largely driven by whether or not they have a fam-
ily history. This idea, however, will require further testing.
Cancer worry was not a predictor of the decision to test as
measured by the participant’s actual behaviour in the past—
specifically, whether or not she tested for BRCA 1 and 2
gene mutations. This probably was due to the majority of
our participants (64%) reporting no cancer worry, consis-
tent with the distribution of cancer worry in both general
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and high-risk populations, but precluding empirical and the-
oretical conclusions (Hay, Buckley & Ostroff, 2004).
Our finding that the decision to test is predicted by pres-
ence of a family member with a positive test result and
Ashkenazi descent must be qualified by the greater likeli-
hood of a physician recommending testing in such individu-
als (Squiers et al., 2010). Thus, in practice, testing is likely
influenced by desire to comply with physician recommen-
dation, though this factor was not examined in the current
study.
We found that the decision to test is predicted by per-
ceived risk of having the mutation (but not perceived risk
of developing breast cancer). This is consistent with re-
search suggesting that risk assessment is not solely through
cognitive lenses, or “risk as analysis”, but is also based
upon instinctive and intuitive reactions, or “risk as feeling”
(Lowenstein, Weber, Hsee & Welch, 2001). That even sub-
jective numeracy did not predict the decision to test sug-
gests that the role of emotion, as expressed by perceived risk
and personal experience, may exceed the role of the cogni-
tive benefits of knowledge from testing. The process might
be such that women feel an “emotional need” to find out
whether they are carriers, which overrides their assessment
of whether they would be able to make use of the informa-
tion. Indeed, research in a variety of contexts has shown that
personal experience has led people to perceive hazards as
more frequent, themselves as potential future victims, and to
think about risk more often and with greater clarity (Lindell
& Perry, 2012; Weinstein, 1989). Health advertising stud-
ies have similarly found that advertisements for DTC tests
are especially effective for women with a higher perceived
threat for developing breast cancer (Rollins, Ramakrishnan
& Perri, 2014). Granted, this possibility should be tested
more directly in this vulnerable population.
Previous work (Miron-Shatz et al., 2014) examined will-
ingness to pay (WTP) for breast cancer testing in this popu-
lation, using only a sub-sample of women who were not pre-
viously tested, and for whom we had data on willingness to
pay (n = 299). They were asked “How much money would
you be willing to spend on getting testing for the BRCA1
and BRCA2 gene mutations?” and were instructed to as-
sume that testing was not covered by their medical insur-
ance. We excluded women who had tested because their
response would likely have been influenced by actual cost
of testing. The main findings were that subjective numeracy
(but not objective numeracy, number of relatives with breast
or ovarian cancer, presence of family member(s) testing pos-
itive, age, Ashkenazi descent, worry that the test might find
illness, perceived risk of developing breast cancer, or edu-
cational level) correlated positively with WTP, as did per-
ceived risk of having a mutation. The contrast between sub-
jective and objective numeracy as predictors of WTP was
replicated here (section 3.2) with a larger sample that in-
cluded those who were tested (n=429).
Unlike that work, the present paper focused on all par-
ticipants who responded to the question on whether they
had previously tested (N =449, though the number of par-
ticipants who had data for all study variables and were in-
cluded in the main analysis was 325). Rather than asking
a hypothetical question, the main dependent variable was a
behavioural one—whether or not the participants had tested
for the BRCA gene mutation. The main predictors here were
family history (number of relatives with breast or ovarian
cancer and relatives who tested positive), perceived risk of
having the mutation, Ashkenazi descent, and age. This is
in keeping with literature suggesting that family history of
breast cancer and perceived risk will increase the likelihood
of testing (Ropka, et al., 2006). Although there has been
ample research into the lower testing rates of other ethno-
religious groups (e.g., Levy, et al., 2011), the higher rate of
Ashkenazi testing seems to be a novel finding.
The numeracy variables, as well as perceived risk of de-
veloping breast cancer, and worry that the test be positive,
were not significant predictors of testing. We suggest inter-
preting the different results obtained in the two studies as re-
flecting whether the decision is made solely (or even mainly)
by the woman, as in the decision of how much to pay for
testing, or also by her physician, by adhering to guidelines
and recommending testing to women with a relevant family
history. This would explain why numeracy variables do not
predict the decision to test and would suggest that, unlike
WTP, decision to test does not depend on the woman’s sense
of how easily she will be able to interpret the testing results.
This is particularly important in view of the abundance of re-
search on WTP, but the relative paucity of research on actual
testing behaviour. The findings suggest that while WTP is
mainly driven by emotional reasons, actual testing is based
primarily on family history, including being of Ashkenazi
descent. It might be that public health efforts to promote
testing should focus on creating clear recommendations and
action paths via healthcare professionals, rather than appeal-
ing to women’s concerns regarding breast cancer. However,
these conclusions must be qualified in that we do not know
which of our participants were indeed referred for testing by
their physicians.
The present results have important practical implications
for both conventional clinic-based testing and any potential
DTC genetic testing. Since perceived risk of having the mu-
tation is a central factor in women’s decision to test, DTC
marketing campaigns may increase anxiety and perceived
risk by exploiting consumers’ emotional concerns (Gollust,
Hull & Wilfond, 2002). Further, upon receipt of DTC test-
ing results, consumers of BRCA test results may experience
anxiety and distress (Dohany, Gustafson, Ducaine & Zaka-
lik, 2012), especially if they receive inadequate counselling
during the process (Brierley et al., 2010). Given our find-
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ings, if the counsellor is aware that family history and emo-
tional relevance may impact the patient’s decision, he/she
will be able to offer better, more cogent advice.
This study has a number of limitations. Among partic-
ipants who had not yet tested, many of their opinions on
the testing process were necessarily hypothetical. For those
who had already undergone BRCA1/2 genetic testing, it was
retrospective. Further, it was the women’s decision to test,
and we did not influence it. These groups relate differently
to their breast cancer risk, and those who have not yet tested
may not follow through on their indicated willingness to test
(Rollins, et al., 2014). Indeed a potential criticism is that
perceived risk may be affected by actual risk for women
who previously tested. However, any such influence on our
results is likely minimal, as the questions were worded to in-
struct women who were previously tested to respond as they
would have prior to testing and the majority of participants
were not tested.
Another limitation is that our sample was composed of
a relatively small group of high-risk, mainly white women,
who may not be representative of other low-risk and non-
white populations. Indeed it may be that high-risk individu-
als have an intuitively better appreciation of risk and impli-
cations of testing. Follow-up studies in larger, more hetero-
geneous samples are needed to confirm our findings. Of the
women we approached, only 48% responded. This response
rate may be attributed to reluctance to delve into their dis-
ease or to more practical reasons, such as the relative length
of the survey.
Further, it is possible that the response rate has made our
sample less representative in terms of the educational level
of the responders. The risk-level limitation, however, is mit-
igated by the fact that BRCA1/2 genetic testing is sought
mainly by women who are at high risk for developing can-
cer or have already been diagnosed with cancer (Ropka et
al., 2006; but see King, Levy-Lahad & Lahad, 2014 who
advocate population-based screening). As such, they are un-
likely to appreciably affect the implications of our findings.
In this regard, rather than a limitation, the sample risk level
may be viewed as a strength, in that our findings are highly
relevant to the women most likely to undergo BRCA 1/2 ge-
netic testing.
The current study explored factors that contribute to
women’s willingness to test for the BRCA1/2 gene or de-
cision to have done so in the past. Findings indicated that
decision to test is influenced most by personal experiences,
especially having relatives who are carriers of the BRCA1/2
gene mutation, or have suffered breast cancer themselves.
Similarly, being of the high-risk Ashkenazi group was also
a major risk factor. Importantly, perceived chance of muta-
tion, an emotional factor, was more predictive of willingness
to test, and decision to test, than more objective numeracy
skills.
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Appendix
Table A1: Demographic and clinical characteristics (N = 459).
Cancer center, % Colorado 34% n=157
Duke 8% 36
Emory 6% 25
Johns Hopkins 13% 60
MD Anderson 6% 25
Univ. of North Carolina 6% 26
Univ. of Utah 28% 129
Age, mean years (sd) 50.44 (7.45) 458
Highest degree or year of school completed, % ≤8 years 34% 157
High School/GED 5% 24
Some College/Technical 22% 101
College+ 72% 329
Marital status, % Single 8% 37




Race, % American Indian/Alaskan Native 1% 4
Asian 1% 3
Black or African American 1% 4
White 96% 438
More than one race 1% 5
Other <1% 1
Tested for BRCA1 or BRCA2 mutation, % No 70% 315
Yes 30% 134
Tested Positive 33% 41
Tested Negative 67% 85
Amount willing to pay (WTP) for BRCA 1/2 testing, Not Tested $143.66 (191.57) 299
mean $ (sd) Tested $925.93 (1342.57) 129
Tested Positive $1466.67 (1739.68) 39
Tested Negative $644.45 (979.81) 82
Objective numeracy23 (range: 0-3), mean (sd) Not Tested 2.01 (0.93) 311
Tested 1.94 (0.94) 133
Subjective numeracy26 (overall SNS score), mean (sd) Not Tested 4.72 (0.83) 315
Tested 4.76 (0.79) 134
Of Ashkenazi (Eastern European Jewish) descent, Not Tested 4% 12 of 315
% of subgroup Tested 23% 31 of 134
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Table A1, continued: Demographic and clinical characteristics (N = 459).
Any family member(s) tested positive for BRCA1 No 27% 123
or BRCA2 mutation, % Yes 8% 38
Unknown 65% 298








Perceived risk of mutation, mean % (sd) Not Tested 32.43% (24.33) 286
Tested 59.22% (21.30) 122
Perceived risk of developing breast cancer, mean % (sd) Not Tested 44.53% (28.52) 288
Tested 60.55% (28.11) 128
Worried that test might find illness, % of subgroup Not Tested
Not Worried at All 59% 186 of 314
Slightly Worried 18% 57 of 314
Of Medium Worry 12% 39 of 314
Worried 6% 19 of 314
Very Worried 4% 13 of 314
Tested
Not Worried at All 71% 93 of 132
Slightly Worried 16% 21 of 132
Of Medium Worry 7% 9 of 132
Worried 7% 9 of 132
Very Worried 0% 0 of 132
All available data shown; amount of missing data varied across the variables. Percentages are out of the total number of
participants with data.
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Table A2: Variables entered at each step in the forward stepwise binary logistic regression predicting previous testing.
Step B S.E. Wald df Sig. Exp(B)
1a Perceived risk of mutation .041 .006 52.352 1 .000 1.042
Constant −2.636 .319 68.112 1 .000 .072
2b Presence of family member(s) testing positive 33.366 2 .000
Presence of family member(s) testing positive (“No”) −2.275 .602 14.255 1 .000 .103
Presence of family member(s) testing positive
(“Unknown/Missing”)
−3.193 .585 29.756 1 .000 .041
Perceived risk of mutation .040 .006 43.243 1 .000 1.041
Constant −.035 .621 .003 1 .955 .965
3c Presence of family member(s) testing positive 28.802 2 .000
Presence of family member(s) testing positive (“No”) −2.156 .624 11.953 1 .001 .116
Presence of family member(s) testing positive
(“Unknown/Missing”)
−3.059 .607 25.417 1 .000 .047
Perceived risk of mutation .039 .006 38.807 1 .000 1.040
Of Ashkenazi descent −1.818 .469 15.017 1 .000 .162
Constant 1.484 .759 3.819 1 .051 4.410
4d Number of relatives with breast or ovarian cancer .170 .075 5.142 1 .023 1.186
Presence of family member(s) testing positive 22.263 2 .000
Presence of family member(s) testing positive (“No”) −1.912 .626 9.334 1 .002 .148
Presence of family member(s) testing positive
(“Unknown/Missing”)
−2.733 .615 19.733 1 .000 .065
Perceived risk of mutation .037 .006 33.676 1 .000 1.037
Of Ashkenazi descent −1.762 .468 14.192 1 .000 .172
Constant .708 .820 .745 1 .388 2.030
5e Number of relatives with breast or ovarian cancer .150 .076 3.861 1 .049 1.161
Presence of family member(s) testing positive 23.337 2 .000
Presence of family member(s) testing positive (“No”) −1.920 .623 9.513 1 .002 .147
Presence of family member(s) testing positive
(“Unknown/Missing”)
−2.790 .614 20.679 1 .000 .061
Age .043 .022 4.009 1 .045 1.044
Perceived risk of mutation .038 .006 34.254 1 .000 1.039
Of Ashkenazi descent −1.825 .487 14.033 1 .000 .161
Constant −1.367 1.326 1.063 1 .302 .255
a. Variable(s) entered on step 1: Perceived risk of mutation.
b. Variable(s) entered on step 2: Presence of family member(s) testing positive.
c. Variable(s) entered on step 3: Of Ashkenazi descent.
d. Variable(s) entered on step 4: Number of relatives with breast or ovarian cancer.
e. Variable(s) entered on step 5: age.
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Table A3: Variables entered at each step in the backward stepwise binary logistic regression predicting previous testing.
Step B S.E. Wald df Sig. Exp(B)
1a Number of relatives with breast or ovarian cancer .152 .077 3.845 1 .050 1.164
Objective Numeracy −.190 .180 1.122 1 .289 .827
Subjective Numeracy −.047 .207 .052 1 .820 .954
Presence of family member(s) testing positive 22.245 2 .000
Presence of family member(s) testing positive (“No”) −1.834 .627 8.555 1 .003 .160
Presence of family member(s) testing positive (“Unknown/Missing”) −2.714 .614 19.513 1 .000 .066
Age .042 .022 3.732 1 .053 1.043
Perceived risk of mutation .036 .008 20.457 1 .000 1.037
Perceived risk of developing breast cancer .004 .007 .283 1 .595 1.004
Worry that the test might find illness −.218 .156 1.943 1 .163 .804
Of Ashkenazi descent −1.817 .497 13.395 1 .000 .162
Constant −.580 1.655 .123 1 .726 .560
2a Number of relatives with breast or ovarian cancer .151 .077 3.844 1 .050 1.164
Objective Numeracy −.204 .168 1.473 1 .225 .815
Presence of family member(s) testing positive 22.223 2 .000
Presence of family member(s) testing positive (“No”) −1.850 .624 8.791 1 .003 .157
Presence of family member(s) testing positive (“Unknown/Missing”) −2.720 .614 19.605 1 .000 .066
Age .042 .022 3.777 1 .052 1.043
Perceived risk of mutation .036 .008 20.447 1 .000 1.037
Perceived risk of developing breast cancer .004 .007 .302 1 .583 1.004
Worry that the test might find illness −.214 .155 1.903 1 .168 .808
Of Ashkenazi descent −1.819 .497 13.416 1 .000 .162
Constant −.785 1.391 .318 1 .573 .456
3a Number of relatives with breast or ovarian cancer .147 .077 3.664 1 .056 1.158
Objective Numeracy −.215 .167 1.663 1 .197 .806
Presence of family member(s) testing positive 22.401 2 .000
Presence of family member(s) testing positive (“No”) −1.840 .626 8.647 1 .003 .159
Presence of family member(s) testing positive (“Unknown/Missing”) −2.728 .617 19.544 1 .000 .065
Age .043 .022 3.979 1 .046 1.044
Perceived risk of mutation .038 .007 34.660 1 .000 1.039
Worry that the test might find illness −.221 .154 2.059 1 .151 .802
Of Ashkenazi descent −1.795 .494 13.230 1 .000 .166
Constant −.718 1.390 .267 1 .606 .488
4a Number of relatives with breast or ovarian cancer .150 .076 3.835 1 .050 1.161
Presence of family member(s) testing positive 22.330 2 .000
Presence of family member(s) testing positive (“No”) −1.860 .622 8.943 1 .003 .156
Presence of family member(s) testing positive (“Unknown/Missing”) −2.723 .613 19.731 1 .000 .066
age .043 .022 3.991 1 .046 1.044
Perceived risk of mutation .038 .007 34.639 1 .000 1.039
Worry that the test might find illness −.189 .151 1.579 1 .209 .828
Of Ashkenazi descent −1.789 .489 13.365 1 .000 .167
Constant −1.183 1.341 .778 1 .378 .306
5a Number of relatives with breast or ovarian cancer .150 .076 3.861 1 .049 1.161
Presence of family member(s) testing positive 23.337 2 .000
Presence of family member(s) testing positive (“No”) −1.920 .623 9.513 1 .002 .147
Presence of family member(s) testing positive (“Unknown/Missing”) −2.790 .614 20.679 1 .000 .061
age .043 .022 4.009 1 .045 1.044
Perceived risk of mutation .038 .006 34.254 1 .000 1.039
Of Ashkenazi descent −1.825 .487 14.033 1 .000 .161
Constant −1.367 1.326 1.063 1 .302 .255
a. Variable(s) entered on step 1: Number of relatives with breast or ovarian cancer, Objective Numeracy, Subjective Numeracy,
Presence of family member(s) testing positive, age, Perceived risk of mutation, Perceived risk of developing breast cancer, Worry that
the test might find illness, Of Ashkenazi descent.
